Aarey Drugs & Pharmaceuticals Reports Strong Q4 FY26 Performance

Net profit for Q4 FY26: ₹1.56 crore
Revenue for Q4 FY26: ₹189.47 crore

Reader Takeaway: Strong Q4 growth driven by operational performance; stable annual profit with focus on warrant fund utilization.

What just happened

Aarey Drugs & Pharmaceuticals Ltd. announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant year-on-year (YoY) increase in net profit for Q4 FY26, which rose by 231.91% to ₹1.56 crore from ₹0.47 crore in Q4 FY25. Revenue from operations also saw substantial growth, increasing by 75.27% to ₹189.47 crore in Q4 FY26, up from ₹108.10 crore in the prior-year period.

For the full fiscal year 2026, Aarey Drugs reported a net profit of ₹3.97 crore, a slight decrease from ₹4.02 crore in FY 2025. Full-year revenue stood at ₹472.27 crore, marginally lower than ₹473.94 crore in FY 2025.

The company also provided details on its corporate actions, noting the utilization of funds from the preferential issue of 50,00,000 convertible warrants allotted on May 23, 2025. As of March 31, 2026, 25% of the consideration, totaling ₹7.98 crore, has been received and utilized.

Why this matters

The strong Q4 performance indicates a potential turnaround or acceleration in the company's business momentum. The significant jump in quarterly profit and revenue suggests improved operational efficiency or increased demand. The stable annual profit provides a baseline, while the utilization of funds from warrants signals that capital raised is being put to use, which is generally viewed positively by investors.

The backstory

In FY 2025, Aarey Drugs & Pharmaceuticals had reported a net profit of ₹4.02 crore on revenues of ₹473.94 crore. The company had previously announced the allotment of convertible warrants, a move aimed at raising capital for its business operations and expansion. The current results reflect the initial impact of these strategic financial moves.

What changes now

Investors will be looking for sustained growth in the coming quarters to confirm if the Q4 performance is a new trend. The effective utilization of the ₹7.98 crore already received from warrants and the planned conversion of the remaining warrants will be key indicators of future capital availability and strategic deployment.

Risks to watch

The auditor's report included an 'Emphasis of Matter' highlighting that debtor and creditor balances are subject to confirmation. This means these balances are relied upon based on management representation, which is a standard audit point but warrants attention. Additionally, some plant and machinery are currently not in a usable state, with no depreciation charged, suggesting ongoing investment in production capacity that is not yet operational.

Peer comparison

While specific peer data was not provided in the filing, the pharmaceutical sector in India is highly competitive, with companies focusing on R&D, manufacturing efficiency, and market access. Aarey Drugs' performance needs to be viewed against the broader industry trends and its specific niche.

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹189.47 crore (vs. ₹108.10 crore in Q4 FY25)
• Q4 FY26 Net Profit: ₹1.56 crore (vs. ₹0.47 crore in Q4 FY25)
• FY 2026 Revenue: ₹472.27 crore (vs. ₹473.94 crore in FY 2025)
• FY 2026 Net Profit: ₹3.97 crore (vs. ₹4.02 crore in FY 2025)
• Warrant Funds Utilized: ₹7.98 crore as of March 31, 2026

What to track next

Investors should monitor the company's progress in converting the remaining warrants, the operationalization of the idle plant and machinery, and any updates on the confirmation of debtor and creditor balances. Continued revenue and profit growth in upcoming quarters will be crucial.